Abstract
Objective:
This study assessed the association between erectile dysfunction (ED) and arthritis.
Methods:
Weighted logistic regression and subgroup analyses were used to investigate the association between arthritis incidence and ED among participants in the 2001–2004 National Health and Nutrition Examination Survey database.
Results:
Among the participants, 27.8% and 18.5% had a self-reported history of ED and arthritis, respectively. ED was associated with arthritis (odds ratio [OR]=4.00; 95% confidence interval [CI]: 3.20–4.99; p<0.001], which remained significant after adjustment (OR=1.42, 95% CI: 1.00–1.96; p<0.001). Stratified by type of arthritis, after full adjustment, osteoarthritis remained significant (OR=1.11; 95% CI: 1.03–1.20; p=0.017), and rheumatoid arthritis (OR=1.03, 95% CI: 0.93–1.13; p= 0.5) and other arthritis (OR=1.04, 95% CI: 0.98–1.11; p=0.2) were not significantly correlated with ED. Multiple inference analyses confirmed the robustness of the results.
Conclusion:
Our study showed that arthritis was strongly associated with ED. There is an urgent need to raise awareness and conduct additional research on the reasons behind this association in order to implement more scientific and rational treatment programs for patients with ED and arthritis.
1 Introduction
Erectile dysfunction (ED) is a common disorder with a prevalence of 46.1% in American men aged 40–70 years, 42.1%–52.5% in European men aged 40–70 years, and 47.4% in Chinese men aged 40–70 years (1). ED is not life-threatening but has an enormous impact on a person’s quality of life because satisfaction with sexuality is a strong predictor of overall life satisfaction (2). Several medical, environmental, psychological, and lifestyle factors (3, 4), including cardiovascular disease, diabetes, hyperlipidemia, hypertension, metabolic syndrome, and psychological distress, have been suggested to contribute to the development of ED.
Another common chronic disease, arthritis, is increasing in prevalence; 49% of adults in the United States are predicted to develop arthritis by 2040 (5). Several previous studies have shown that various types of arthritis, including osteoarthritis (OA) (6), rheumatoid arthritis (RA) (7), gout (8), and psoriatic arthritis (9), are associated with an increased risk of ED. This may be due to the fact that arthritis, as a chronically systemic inflammatory disease, affects a wide range of systems throughout the body, including the reproductive system (10). However, some researchers found no clear association between RA and ED after deeper exploration (11). Overall, the relationship between arthritis and ED is complex and requires intensive research.
Therefore, this study investigated the relationship between arthritis and ED using data from the National Health and Nutrition Examination Survey (NHANES) from 2001–2004.
2 Materials and methods
2.1 Study population
The data utilized in this study were procured from the National Health and Nutrition Examination Survey (NHANES), which is conducted annually by the National Center for Health Statistics (NCHS), a division of the Centers for Disease Control and Prevention, with the objective of assessing the health status and behavior of unstructured populations in the United States (12). A complex multistage probability sampling design was employed in the NHANES survey to collect data representative of the population (13). All NHANES procedures were approved by the U.S. Policy for the Protection of Human Research Subjects and were reviewed and standardized annually by the NCHS Research Ethics Review Board. All individuals who participated in the survey provided informed consent, indicating their understanding of the study’s purpose.
For the purposes of this cross-sectional analysis, datasets were selected from two NHANES survey cycles: 2001–2002 and 2003–2004, because only these two cycles had complete ED and arthritis data. A total of 21,161 individuals participated in the NHANES from 2001 to 2004; the exclusion criteria were as follows: female (n=10,860) and male patients aged less than 20 years (n=5,347), missing information on ED or arthritis (n=846), and missing covariate information (n=462). A total of 3,646 patients were ultimately included in this study. Of these, 1,012 patients had a self-reported history of ED, and 795 patients had a self-reported history of arthritis.
2.2 Data collection and definition
We used the NHANES self-report questionnaire to diagnose ED and arthritis. All participants were asked the ED-related question, “How would you describe your ability to develop and maintain an erection sufficient for sexual intercourse?” The answers were “never,” “sometimes,” “usually,” or “almost always or nearly always.” We categorized those who answered “never” or “sometimes” as having ED. All participants were asked two questions related to arthritis. First, they were asked, “Has any doctor or other health professional ever told you that you have arthritis?” Individuals who provided a positive response were asked the follow-up question, “What type of arthritis is it?” Participants were categorized as having “no arthritis,” “rheumatoid arthritis,” “osteoarthritis,” or “other types of arthritis.”
Using multivariate-adjusted models, we identified potential confounders that may influence the association between arthritis and ED. The covariates included age, race, body mass index, weight-adjusted-waist index (WWI) (14, 15), marital status (married or living with a partner/single), poverty-to-income ratio, education level, exercise status, insurance status, alcohol consumption (whether they consumed alcohol or not), smoking status (current/former/no), hypertension, diabetes, hypercholesterolemia, cardiovascular disease, stroke, and prostate disease.
2.3 Statistical methods
Complex sample weights were used to address sample inclusion selection, oversampling, and non-response bias. Overall incidences of ED and arthritis were estimated using complex sample weights. Time trends in ED and arthritis incidence were assessed after adjusting for age and race. Categorical variables were compared using the card method. Logistic regression modeling was used to adjust for covariates. Odds ratios (ORs) were calculated for 95% confidence intervals (CIs) and p values. We performed sensitivity analyses of the results using multiple interpolations, which first imputed five sets of complete datasets by calling the mouse function. Subsequently, statistical analyses, such as univariate analysis and regression models, were performed within each dataset by calling a function which sets the environment for the statistical analysis. Finally, the results obtained from each analysis were combined using the pool function (16), a method of compensating for missing data based on five replicates, and the chained equation method in the Remote Method Invocation procedure to account for the effect of missing covariates on the results (17). Subgroup analyses were performed using weighted multivariate logistic regression (Model 4) for different strata of our cohort in which the association between arthritis and ED was analyzed. All statistical tests were two-sided, with a significance threshold of p<0.05. R version 4.3.2 (http://www.R-project.org, The R Foundation) was used for statistical analysis.
3 Results
3.1 Characteristics of the study participants
Between 2001 and 2004, 21,161 participants were interviewed. Of these, 4,954 were men aged over 20 years. A total of 4,108 (83.0%) participants answered the survey questions on ED and arthritis. After adjusting for missing covariate values, 3,646 participants were included in the cohort (Figure 1).
Figure 1
Schematic flow diagram of the inclusion and exclusion criteria for our study cohort.
Compared with participants without ED, those with ED had higher rates of all types of arthritis (p<0.001) and were more likely to be older, less educated, married or living with a sexual partner, socioeconomically disadvantaged, physically inactive, insured, not alcohol consumers, former smokers, not hypertensive, and unhealthy in terms of diabetes mellitus, dyslipidemia, obesity, cardiovascular disease, and prostate disease. No significant race differences were observed between the ED and non-ED groups (Table 1).
Table 1
| Characteristic | Overall n= 79259578 N = 3646 |
Erectile Dysfunction | P Value | |
|---|---|---|---|---|
| No ED n= 64436827 N = 2634 |
ED n= 14822751 N = 1012 |
|||
| Age (years) | 44.9 ± 15.7 | 41.2 ± 13.3 | 61.0 ± 15.2 | <0.001 |
| Race | 0.2 | |||
| Mexican American | 747 (7.7%) | 537 (7.9%) | 210 (6.8%) | |
| Other Hispanic | 122 (4.3%) | 87 (4.1%) | 35 (5.1%) | |
| Non-Hispanic White | 1,993 (74.5%) | 1,394 (73.9%) | 599 (77.0%) | |
| Non-Hispanic Black | 675 (9.5%) | 526 (9.8%) | 149 (8.2%) | |
| Other Race | 109 (4.0%) | 90 (4.3%) | 19 (2.9%) | |
| BMI(kg/m2) | 28.0 ± 5.4 | 27.8 ± 5.2 | 28.9 ± 6.1 | 0.002 |
| WWI | 10.7 ± 0.7 | 10.6 ± 0.7 | 11.2 ± 0.7 | <0.001 |
| Diabetes | <0.001 | |||
| No | 3,226 (92.0%) | 2,472 (95.6%) | 754 (76.7%) | |
| Yes | 372 (7.0%) | 133 (3.5%) | 239 (22.0%) | |
| Borderline | 48 (1.0%) | 29 (0.9%) | 19 (1.3%) | |
| Hypertension | 2,170 (65.7%) | 1,797 (71.3%) | 373 (41.3%) | <0.001 |
| High cholesterol | 1,344 (36.6%) | 856 (32.9%) | 488 (52.4%) | <0.001 |
| Cardiovascular disease | 408 (8.1%) | 159 (4.6%) | 249 (23.0%) | <0.001 |
| Stroke | 117 (1.8%) | 33 (0.8%) | 84 (6.2%) | <0.001 |
| Prostate disease | 534 (10.7%) | 205 (6.7%) | 329 (27.8%) | <0.001 |
| Smoking | <0.001 | |||
| Nonsmoker | 1,471 (42.5%) | 1,166 (45.3%) | 305 (30.3%) | |
| Former smoker | 1,190 (29.4%) | 686 (25.3%) | 504 (46.9%) | |
| Current smoker | 985 (28.1%) | 782 (29.4%) | 203 (22.7%) | |
| Alcohol intake | 3,029 (83.9%) | 2,209 (84.5%) | 820 (81.0%) | 0.042 |
| Physical Activity | <0.001 | |||
| Inactive | 1,361 (30.9%) | 874 (28.3%) | 487 (42.4%) | |
| Moderate | 1,033 (29.2%) | 684 (27.2%) | 349 (37.6%) | |
| Vigorous | 1,252 (39.9%) | 1,076 (44.5%) | 176 (20.0%) | |
| Insurance | 2,887 (80.9%) | 1,981 (78.7%) | 906 (90.5%) | <0.001 |
| Education level | <0.001 | |||
| < High school | 1,009 (16.6%) | 608 (13.9%) | 401 (28.4%) | |
| High school | 894 (26.9%) | 684 (27.6%) | 210 (23.5%) | |
| > High school | 1,743 (56.5%) | 1,342 (58.5%) | 401 (48.1%) | |
| Marital status | <0.001 | |||
| Married or living with partner | 2,523 (70.2%) | 1,769 (68.6%) | 754 (76.9%) | |
| Living alone | 1,123 (29.8%) | 865 (31.4%) | 258 (23.1%) | |
| Poverty-income ratio | <0.001 | |||
| <1.5 | 1,028 (19.0%) | 706 (18.5%) | 322 (21.6%) | |
| 1.5-3.5 | 1,258 (32.8%) | 864 (31.4%) | 394 (38.8%) | |
| over 3.5 | 1,360 (48.1%) | 1,064 (50.1%) | 296 (39.6%) | |
| Arthritis | <0.001 | |||
| No Arthritis | 2,851 (81.5%) | 2,229 (86.2%) | 622 (61.1%) | |
| RA | 164 (3.6%) | 86 (2.8%) | 78 (6.9%) | |
| OA | 228 (5.2%) | 103 (3.3%) | 125 (13.6%) | |
| Others | 403 (9.7%) | 216 (7.6%) | 187 (18.4%) | |
Baseline characteristics of Erectile Dysfunction group versus the non-Erectile Dysfunction group.
1. Mean ± SD; n (unweighted) (%), 2. Wilcoxon rank-sum test for complex survey samples; chi-squared test with Rao & Scott’s second-order correction.
Participants with arthritis had a greater rate of having ED than did those without arthritis (p<0.001) and were older, less educated, predominantly non-Hispanic white (especially those with OA), married or living with a sexual partner, socioeconomically disadvantaged, physically inactive, insured, not alcohol consumers, ex-smokers, non-hypertensive, and had diabetes mellitus, dyslipidemia, obesity, and unhealthy in terms of cardiovascular or prostate disease. There were no significant differences in alcohol consumption between the groups with and without arthritis (Table 2).
Table 2
| Characteristic | Arthritis | P Value | ||||
|---|---|---|---|---|---|---|
| No Arthritis n=64626120 N=2851 | Total Arthritis n=14633459 N=795 | RA n=2852317 N=164 | OA n=4127543 N=228 | Others n=7653599 N =403 | ||
| Age (years) | 42.4 ± 14.8 | 56.1 ± 14.6 | 55.2 ± 13.7 | 60.0 ± 13.4 | 54.3 ± 15.1 | <0.001 |
| Race | <0.001 | |||||
| Mexican American | 633 (8.7%) | 114 (3.3%) | 23 (3.4%) | 20 (2.1%) | 71 (4.0%) | |
| Other Hispanic | 110 (4.9%) | 12 (1.6%) | 5 (4.2%) | 4 (1.4%) | 3 (0.8%) | |
| Non-Hispanic White | 1,467 (72.3%) | 526 (84.2%) | 96 (79.5%) | 174 (88.1%) | 256 (83.8%) | |
| Non-Hispanic Black | 547 (9.8%) | 128 (8.0%) | 37 (11.3%) | 26 (5.5%) | 65 (8.0%) | |
| Other Race | 94 (4.3%) | 15 (2.9%) | 3 (1.6%) | 4 (2.8%) | 8 (3.4%) | |
| BMI(kg/m2) | 27.7 ± 5.2 | 29.4 ± 6.2 | 29.0 ± 7.3 | 30.4 ± 6.5 | 29.0 ± 5.5 | <0.001 |
| WWI | 10.6 ± 0.7 | 11.1 ± 0.7 | 11.1 ± 0.7 | 11.2 ± 0.6 | 11.0 ± 0.7 | <0.001 |
| Diabetes | <0.001 | |||||
| No | 2,591 (93.9%) | 635 (83.7%) | 133 (83.2%) | 180 (82.1%) | 322 (84.8%) | |
| Yes | 229 (5.2%) | 143 (14.6%) | 26 (12.4%) | 42 (16.6%) | 75 (14.4%) | |
| Borderline | 31 (0.9%) | 17 (1.7%) | 5 (4.5%) | 6 (1.3%) | 6 (0.9%) | |
| Hypertension | 1,858 (70.5%) | 312 (44.4%) | 64 (45.8%) | 79 (37.9%) | 169 (47.4%) | <0.001 |
| High cholesterol | 937 (33.0%) | 407 (52.1%) | 80 (48.8%) | 132 (58.5%) | 195 (49.8%) | <0.001 |
| Cardiovascular disease | 218 (5.4%) | 190 (19.8%) | 39 (21.0%) | 62 (23.4%) | 89 (17.4%) | <0.001 |
| Stroke | 63 (1.1%) | 54 (5.1%) | 15 (5.5%) | 11 (3.8%) | 28 (5.8%) | <0.001 |
| Prostate disease | 303 (7.8%) | 231 (23.3%) | 37 (16.6%) | 86 (31.9%) | 108 (21.2%) | <0.001 |
| Smoking | <0.001 | |||||
| Nonsmoker | 1,227 (45.0%) | 244 (31.6%) | 31 (16.0%) | 69 (31.1%) | 144 (37.7%) | |
| Former smoker | 822 (26.6%) | 368 (41.7%) | 73 (41.2%) | 123 (49.3%) | 172 (37.8%) | |
| Current smoker | 802 (28.4%) | 183 (26.7%) | 60 (42.8%) | 36 (19.7%) | 87 (24.5%) | |
| Alcohol intake | 2,382 (84.5%) | 647 (81.2%) | 133 (79.4%) | 189 (83.0%) | 325 (80.8%) | 0.071 |
| Physical Activity | <0.001 | |||||
| Inactive | 1,012 (28.8%) | 349 (40.0%) | 80 (44.5%) | 86 (33.6%) | 183 (41.9%) | |
| Moderate | 743 (27.6%) | 290 (36.1%) | 57 (35.5%) | 97 (43.2%) | 136 (32.5%) | |
| Vigorous | 1,096 (43.6%) | 156 (23.9%) | 27 (20.0%) | 45 (23.2%) | 84 (25.7%) | |
| Education level | <0.001 | |||||
| < High school | 746 (15.4%) | 263 (22.0%) | 64 (29.0%) | 56 (17.7%) | 143 (21.7%) | |
| High school | 703 (26.5%) | 191 (28.6%) | 41 (29.8%) | 52 (26.9%) | 98 (29.1%) | |
| > High school | 1,402 (58.2%) | 341 (49.4%) | 59 (41.2%) | 120 (55.4%) | 162 (49.2%) | |
| Marital status | <0.001 | |||||
| Married or living with partner | 1,921 (68.4%) | 602 (78.1%) | 112 (70.9%) | 187 (82.4%) | 303 (78.5%) | |
| Living alone | 930 (31.6%) | 193 (21.9%) | 52 (29.1%) | 41 (17.6%) | 100 (21.5%) | |
| Poverty-income ratio | 0.018 | |||||
| <1.5 | 786 (18.4%) | 242 (21.8%) | 64 (35.5%) | 53 (16.9%) | 125 (19.2%) | |
| 1.5-3.5 | 976 (32.2%) | 282 (35.3%) | 56 (31.6%) | 87 (38.4%) | 139 (35.1%) | |
| over 3.5 | 1,089 (49.3%) | 271 (42.9%) | 44 (32.9%) | 88 (44.7%) | 139 (45.7%) | |
| Insurance | 2,154 (78.6%) | 733 (91.2%) | 143 (86.2%) | 213 (92.0%) | 377 (92.6%) | <0.001 |
| erectical dysfunction | <0.001 | |||||
| No ED | 2,229 (86.0%) | 405 (60.6%) | 86 (64.0%) | 103 (51.1%) | 216 (64.4%) | |
| ED | 622 (14.0%) | 390 (39.4%) | 78 (36.0%) | 125 (48.9%) | 187 (35.6%) | |
Baseline characteristics of arthritis group versus the non-arthritis group.
1. Mean ± SD; n (unweighted) (%), 2. Wilcoxon rank-sum test for complex survey samples; chi-squared test with Rao & Scott’s second-order correction.
3.2 Association between arthritis and ED
Weighted logistic regression analysis revealed a significant positive association between arthritis and ED in all models. According to the fully adjusted model (Model 4), compared with patients without arthritis, patients with arthritis had a 42% greater risk of ED (OR=1.42; 95% CI: 1.00–1.96; p= 0.006); sensitivity analyses showed similar results in the fully adjusted model (OR=1.34; 95% CI: 1.04–1.74; p= 0.009) (Table 3). Among the different types of arthritis, OA was significantly associated with ED (OR = 1.11; 95% CI: 1.03–1.20; p = 0.017). Sensitivity analyses revealed similar results in the fully adjusted models (OR=1.10; 95% CI: 1.03–1.19); however, RA (OR=1.03, 95% CI: 0.93–1.13; p= 0.5) and other types of arthritis (OR=1.04; 95% CI: 0.98–1.11; p= 0.2) were not significantly associated with ED (Table 3).
Table 3
| All arthritis and ED | RA and ED | |||||||
|---|---|---|---|---|---|---|---|---|
| Complete case | Multiple imputation | Complete case | Multiple imputation | |||||
| OR(95% CI) | p-value | OR(95% CI) | p-value | OR(95% CI) | p-value | OR(95% CI) | p-value | |
| Crude Model | 4.00(3.20, 4.99) | <0.001 | 3.96(3.26,4.82) | <0.001 | 1.25(1.14, 1.36) | <0.001 | 1.22(1.12, 1.33) | <0.001 |
| Model1 | 1.90 (1.42, 2.53) | <0.001 | 1.74(1.34,2.25) | <0.001 | 1.08 (1.00, 1.17) | 0.06 | 1.05 (0.97, 1.14) | 0.2 |
| Model2 | 1.58 (1.16, 2.16) | <0.001 | 1.48(1.14,1.92) | 0.002 | 1.04 (0.95, 1.14) | 0.4 | 1.01 (0.93, 1.11) | 0.8 |
| Model3 | 1.63 (1.25, 2.12) | <0.001 | 1.51(1.18,1.93) | <0.001 | 1.06 (0.98, 1.14) | 0.2 | 1.03 (0.95, 1.11) | 0.4 |
| Model4 | 1.42(1.00, 1.96) | 0.006 | 1.34(1.04,1.74) | 0.009 | 1.03(0.93, 1.13) | 0.5 | 1.00(0.91, 1.10) | >0.9 |
| OA and ED | Other arthritis and ED | |||||||
| Complete case | Multiple imputation | Complete case | Multiple imputation | |||||
| OR(95% CI) | p-value | OR(95% CI) | p-value | OR(95% CI) | p-value | OR(95% CI) | p-value | |
| Crude Model | 1.42(1.30, 1.54) | <0.001 | 1.41(1.31, 1.52) | <0.001 | 1.24(1.17, 1.32) | <0.001 | 1.26(1.20, 1.33) | <0.001 |
| Model1 | 1.16 (1.08, 1.25) | <0.001 | 1.14 (1.07, 1.23) | <0.001 | 1.09(1.02, 1.15) | 0.008 | 1.09(1.03, 1.15) | 0.003 |
| Model2 | 1.15 (1.06, 1.23) | 0.002 | 1.13 (1.06, 1.22) | 0.002 | 1.07(1.01, 1.14) | 0.035 | 1.07(1.01, 1.13) | 0.018 |
| Model3 | 1.12 (1.05, 1.20) | 0.003 | 1.11 (1.04, 1.18) | 0.004 | 1.05(1.00, 1.11) | 0.062 | 1.06(1.01, 1.11) | 0.031 |
| Model4 | 1.11(1.03, 1.20) | 0.017 | 1.10(1.03, 1.19) | 0.017 | 1.04(0.98, 1.11) | 0.2 | 1.05(0.99, 1.11) | 0.1 |
Association between Arthritis and ED.
Crude model: no adjusted model; Model 1: adjusted for age, race; Model 2: adjusted for age, race, the family income-to-poverty ratio, education level, marital status, BMI, WWI, alcohol intake,smoking status, physical activity status, Insurance; Model 3: adjusted for age, race, cardiovascular disease, diabetes, hypertension, high cholesterol, stroke, prostate disease; Model 4: adjusted all; OR, Odds Ratio; CI, Confidence Interval.Bold and italicized values indicate p-values <0.05, which is significant.
3.3 Subgroup analysis of the incidence of arthritis and ED
Subgroup analyses revealed a consistent positive correlation between the incidence of arthritis and ED across the subgroups, indicating the robustness of this correlation. Significance was maintained in the following subgroups: age <60 years, White, and no alcohol consumption (p<0.05) (Figure 2).
Figure 2
Subgroup analysis of the association between arthritis and ED status.
4 Discussion
In a pooled analysis of a nationally representative sample of 3,646 men aged >20 years in the United States, we observed a positive association between arthritis and ED incidence. This association persisted, even after adjusting for confounders. Based on the large sample size and reasonable quality control, our analysis is reliable. Previous studies have reported a higher incidence of ED in patients with inflammatory arthropathies (including RA and psoriatic arthritis) (18), ankylosing spondylitis (19), and gout (20), compared with the general population without arthritis. Similarly, in this study, 39.4% of patients with arthritis developed ED, which was much greater than the 14.0% among those without arthritis. After adjusting for confounders among the different types of arthritis, we observed that the effect of arthritis on ED incidence remained significant in patients with OA, whereas there was no significant association between RA or other types of arthritis and ED. According to our interaction analysis, White race played a role in modifying the association between arthritis and ED, with White individuals showing stronger associations, compared with other races, which may be related to the greater probability of ED disclosure in the White population (21).
According to the age-stratified analyses, there was a strong correlation between ED and the incidence of arthritis. However, the correlation between ED and arthritis found in the present study did not increase with age; rather, it was more significant in participants aged less than 60 years. Although the prevalence of arthritis in older adults is relatively high at present, it is predicted that adults aged 18–65 years will account for the majority of arthritis cases (67%) by 2040 (5); therefore, the relationship between arthritis and ED is not entirely due to aging. Moreover, previous scholars have noted that lack of exercise (22) and abnormal WWIs can lead to both arthritis and ED (14, 15). However, in the present study, after adjusting for the amount of exercise and WWI, the association between arthritis and ED remained significant. Thus, they were not the main common causes of either disorder.
The biological mechanism of inflammation may be closely related to ED in men with arthritis. It has been shown that tumor necrosis factor (TNF)-α, interleukin (IL)-1β are significantly increased in patients with OA, RA, ankylosing spondylitis, and psoriatic arthritis (18, 23). TNF-α plays a specific role in inflammation-associated ED by increasing arterial reactive oxygen species and decreasing nitric oxide levels (24), leading to deterioration of endothelium-dependent vasodilatory function in different vascular regions. Nishimatsu found that injection of the pro-inflammatory cytokine-, TNF-α-, and IL-1β-producing senescent cells in mice can impair erectile response by triggering endothelial dysfunction and nerve damage (25). Additionally, as an essential treatment for various types of arthritis, anti-TNF-α treatments play an important role in preventing the development of cavernous body dysfunction (26, 27). Zuo et al. also showed that an inflammatory state-induced decrease in endothelial nitric oxide synthase and nitric oxide levels may contribute to ED development in rats (28).
Further, Wade noted that men with moderate or severe pain had more erectile difficulties than did those without pain (29). In addition, the use of nonsteroidal anti-inflammatory drugs (NSAIDs), basic medications used in the treatment of various types of arthritis, has been shown to increase the risk of ED (30, 31). In a large clinical study, a 22% and 38% increase in the prevalence of any ED and severe ED, respectively, was observed in a group of individuals who used NSAIDs (32). Similarly, a prospective observational study in Finland (33) found a relatively increased risk of ED in men with arthritis, and men with or without arthritis that used NSAIDs had a higher risk of ED than did men who did not use NSAIDs and did not have arthritis. In addition, anti-inflammatory pain and diclofenac have been observed to inhibit the erectile process by decreasing nitric oxide levels in rats (34). Another study indicated that celecoxib might induce ED by affecting the source of reactive oxygen species, thus modulating nitric oxide breakdown (35, 36). In addition, other types of analgesics, such as opioid analgesics (37), also increase the risk of ED. Therefore, pain and analgesics may serve as a bridge between arthritis and ED.
In addition, it has been shown that the specific expression of cyclooxygenase-2 (COX-2), which plays an important role in the inflammatory microenvironment, promotes inflammatory factor-induced imbalances in cartilage proteoglycan metabolism, leading to irreversible advancement of arthritis (38). Fan et al. showed that COX-2 mRNA and protein levels were significantly higher in the synoviocytes of patients with OA and RA than in healthy tissues and were significantly higher in patients with OA than in those with RA (p < 0.05) (39). Interestingly, COX-2 protein levels are significantly elevated in the synovial fluid of patients with OA but not in those with RA (39). Moreover, it has been noted that the inflammatory state of autoimmune arthritis is associated with a bio-clock (40) that is cyclical, whereas OA usually exhibits a persistent inflammatory state. As a result, the level of inflammation in OA is higher for a longer duration than in RA, and the frequency and amount of analgesics used are increased (41). These factors may be important in the close relationship between OA and ED.
This study has several strengths. First, the survey is based on a large sample size and complex survey design, providing a comprehensive overview of the US population. Second, we adjusted for as many covariates as possible, such as general information, income, health behaviors, and comorbidities, which made our results more robust. Ultimately, the extensive data set permitted the implementation of subgroup analyses while maintaining an acceptable level of statistical power, further validating the stability of our results. However, this study has some limitations. First, because this was a cross-sectional study, causal inferences regarding arthritis and ED are not feasible. Second, the diagnoses of ED and arthritis were based on self-reported questionnaires, which may have led to misestimation of the actual number of patients with ED and arthritis. Previous studies have tested the validity of a single self-report questionnaire (42, 43). Third, our analyses were based only on the US population; therefore, the applicability of our conclusions to other populations remains to be determined. Fourth, some covariates were excluded from the analyses, such as mental illness-related cofounders (depression and anxiety), because data were not available for all participants. Finally, observational studies are susceptible to residual confounders, even after controlling for potential confounders. However, this is the first study to identify correlations between all types of arthritis and ED. We performed sensitivity analyses, and these correlations remained significant.
In conclusion, our results suggest that patients with arthritis are significantly more likely to have ED than are those without arthritis, and that arthritis is significantly associated with ED. Timely identification and treatment of ED in patients with arthritis can have a significant impact on their quality of life by avoiding the use of costly healthcare. In the future, we hope that relevant research will be conducted on populations of more races. Further research is needed to investigate the underlying molecular mechanisms to take appropriate therapeutic measures for patients with arthritis and ED.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.
Ethics statement
The studies involving humans were approved by THE NHANES Institutional Review Board (IRB) Protocol #98-12. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
CL: Data curation, Formal analysis, Methodology, Software, Validation, Visualization, Writing – original draft. WL: Conceptualization, Funding acquisition, Investigation, Project administration, Resources, Writing – review & editing. QL: Conceptualization, Data curation, Funding acquisition, Investigation, Supervision, Writing – original draft. JL: Project administration, Resources, Writing – review & editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was funded by the 1Science and Technology Project of Quanzhou City (2023N065S) and 2Natural Science Foundation of Fujian Province (2021J01266).
Acknowledgments
We are grateful to all the participants involved in the present study for their enthusiasm and commitment.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Goldstein I Goren A Li VW Tang WY Hassan TA . Epidemiology update of erectile dysfunction in eight countries with high burden. Sexual Med Rev. (2020) 8:48–58. doi: 10.1016/j.sxmr.2019.06.008
2
Althof SE . Quality of life and erectile dysfunction. Urology. (2002) 59:803–10. doi: 10.1016/S0090-4295(02)01606-0
3
Lewis RW Fugl-Meyer KS Corona G Hayes RD Laumann EO Moreira ED Jr. et al . Definitions/epidemiology/risk factors for sexual dysfunction. J sexual Med. (2010) 7:1598–607. doi: 10.1111/j.1743-6109.2010.01778.x
4
Sooriyamoorthy T Leslie SW . Erectile dysfunction. In: StatPearls. StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC, Treasure Island (FL (2023). with ineligible companies. Disclosure: Stephen Leslie declares no relevant financial relationships with ineligible companies.
5
Hootman JM Helmick CG Barbour KE Theis KA Boring MA . Updated projected prevalence of self-reported doctor-diagnosed arthritis and arthritis-attributable activity limitation among US adults, 2015-2040. Arthritis Rheumatol (Hoboken NJ). (2016) 68:1582–7. doi: 10.1002/art.39692
6
Blake DJ Maisiak R Koplan A Alarcón GS Brown S . Sexual dysfunction among patients with arthritis. Clin Rheumatol. (1988) 7:50–60. doi: 10.1007/BF02284057
7
El Miedany Y El Gaafary M El Aroussy N Youssef S Ahmed I . Sexual dysfunction in rheumatoid arthritis patients: arthritis and beyond. Clin Rheumatol. (2012) 31:601–6. doi: 10.1007/s10067-011-1891-2
8
Dehlin M Jacobsson L Roddy E . Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. (2020) 16:380–90. doi: 10.1038/s41584-020-0441-1
9
Kurizky PS Mota LM . Sexual dysfunction in patients with psoriasis and psoriatic arthritis–a systematic review. Rev Bras Reumatol. (2012) 52:943–8. doi: 10.1590/S0482-50042012000600011
10
Cutolo M Sulli A Pizzorni C Craviotto C Straub RH . Hypothalamic-pituitary-adrenocortical and gonadal functions in rheumatoid arthritis. Ann N Y Acad Sci. (2003) 992:107–17. doi: 10.1111/j.1749-6632.2003.tb03142.x
11
Wilton KM Achenbach SJ Davis JM 3rd Myasoedova E Matteson EL Crowson CS . Erectile dysfunction and cardiovascular risk in men with rheumatoid arthritis: A population-based cohort study. J Rheumatol. (2021) 48:1641–7. doi: 10.3899/jrheum.201226
12
Mao W Wu J Zhang Z Xu Z Xu B Chen M . Neutrophil-lymphocyte ratio acts as a novel diagnostic biomarker for kidney stone prevalence and number of stones passed. Trans andrology urol. (2021) 10:77–86. doi: 10.21037/tau
13
Mao W Hu Q Chen S Chen Y Luo M Zhang Z et al . Polyfluoroalkyl chemicals and the risk of kidney stones in US adults: A population-based study. Ecotoxicol Environ safety. (2021) 208:111497. doi: 10.1016/j.ecoenv.2020.111497
14
Cao S Hu X Shao Y Wang Y Tang Y Ren S et al . Relationship between weight-adjusted-waist index and erectile dysfunction in the United State: results from NHANES 2001-2004. Front endocrinol. (2023) 14:1128076. doi: 10.3389/fendo.2023.1128076
15
Wang X Xie L Yang S . Association between weight-adjusted-waist index and the prevalence of rheumatoid arthritis and osteoarthritis: a population-based study. BMC musculoskeletal Disord. (2023) 24:595. doi: 10.1186/s12891-023-06717-y
16
Zhang Z . Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med. (2016) 4:30. doi: 10.3978/j.issn.2305-5839.2015.12.63
17
Li Y Ji L Oravecz Z Brick TR Hunter MD Chow SM . dynr.mi: An R Program for Multiple Imputation in Dynamic Modeling. World academy of science, engineering and technology. World Acad Sci Eng Technol. (2019) 13(5):302–11. doi: 10.5281/zenodo.3298841
18
Perez-Garcia LF Röder E Goekoop RJ Hazes JMW Kok MR Smeele HTW et al . Impaired fertility in men diagnosed with inflammatory arthritis: results of a large multicentre study (iFAME-Fertility). Ann rheumati diseases. (2021) 80:1545–52. doi: 10.1136/annrheumdis-2021-220709
19
Santana T Skare T Delboni VS Simione J Campos APB Nisihara R . Erectile dysfunction in ankylosing spondylitis patients. Int Braz J urol. (2017) 43:730–5. doi: 10.1590/s1677-5538.ibju.2016.0378
20
Abdul Sultan A Mallen C Hayward R Muller S Whittle R Hotston M et al . Gout and subsequent erectile dysfunction: a population-based cohort study from England. Arthritis Res Ther. (2017) 19:123. doi: 10.1186/s13075-017-1322-0
21
Gaines JM Macdonald EJ Smith AJ Diefenbach MA Paduch DA . Race and ethnicity have a significant effect on the disclosure of erectile function: an analysis of NHANES response patterns. Urology. (2022) 167:138–43. doi: 10.1016/j.urology.2022.05.031
22
Booth FW Roberts CK Laye MJ . Lack of exercise is a major cause of chronic diseases. Compr Physiol. (2012) 2:1143–211. doi: 10.1002/cphy.c110025
23
Kulkarni P Martson A Vidya R Chitnavis S Harsulkar A . Pathophysiological landscape of osteoarthritis. Adv Clin Chem. (2021) 100:37–90. doi: 10.1016/bs.acc.2020.04.002
24
Carneiro FS Webb RC Tostes RC . Emerging role for TNF-α in erectile dysfunction. J Sex Med. (2010) 7:3823–34. doi: 10.1111/j.1743-6109.2010.01762.x
25
Nishimatsu H Suzuki E Saito Y Niimi A Nomiya A Fukuhara H et al . Senescent cells impair erectile function through induction of endothelial dysfunction and nerve injury in mice. PLoS One. (2015) 10:e0124129. doi: 10.1371/journal.pone.0124129
26
Maruotti N d'Onofrio F Cantatore FP . Metabolic syndrome and chronic arthritis: effects of anti-TNF-α therapy. Clin Exp Med. (2015) 15:433–8. doi: 10.1007/s10238-014-0323-4
27
Demirtaş Şahin T Yazir Y Utkan T Gacar G Halbutoğulları ZS Gocmez SS . Depression induced by chronic stress leads to penile cavernosal dysfunction: protective effect of anti-TNF-α treatment. Can J Physiol Pharmacol. (2018) 96:933–42. doi: 10.1139/cjpp-2017-0778
28
Zuo Z Jiang J Jiang R Chen F Liu J Yang H et al . Effect of periodontitis on erectile function and its possible mechanism. J Sex Med. (2011) 8:2598–605. doi: 10.1111/j.1743-6109.2011.02361.x
29
Wade K Wu FCW O’Neill TW Lee DM . Association between pain and sexual health in older people: results from the English Longitudinal Study of Ageing. Pain. (2018) 159:460–8. Li, T., et al., Association between use of aspirin or non-aspirin non-steroidal anti-inflammatory drugs and erectile dysfunction: a systematic review. Medicine (Baltimore), 2018. 97(28): e11367. doi: 10.1097/MD.0000000000011367
30
Zheng SL Roddick AJ . Association of aspirin use for primary prevention with cardiovascular events and bleeding events: A systematic review and meta-analysis. JAMA. (2019) 321:277–87. doi: 10.1001/jama.2018.20578
31
Patel DP Schenk JM Darke A Myers JB Brant WO Hotaling JM . Non-steroidal anti-inflammatory drug (NSAID) use is not associated with erectile dysfunction risk: results from the Prostate Cancer Prevention Trial. BJU Int. (2016) 117:500–6. doi: 10.1111/bju.13264
32
Gleason JM Slezak JM Jung H Reynolds K Van den Eeden SK Haque R et al . Regular nonsteroidal anti-inflammatory drug use and erectile dysfunction. J Urol. (2011) 185:1388–93. doi: 10.1016/j.juro.2010.11.092
33
Shiri R Koskimäki J Häkkinen J Tammela TL Auvinen A Hakama M . Effect of nonsteroidal anti-inflammatory drug use on the incidence of erectile dysfunction. J Urol. (2006) 175:1812–5; discussion 1815-6. doi: 10.1016/S0022-5347(05)01000-1
34
Senbel AM . Functional inhibition of erectile process in rats by indomethacin. World J Urol. (2011) 29:523–7. doi: 10.1007/s00345-010-0600-0
35
Dhikav V Gupta S Anand KS . Erectile dysfunction induced probably by celecoxib. Pharmacoepidemiol Drug Saf. (2008) 17:211–2. doi: 10.1002/pds.1539
36
O'Banion MK . Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol. (1999) 13:45–82. doi: 10.1615/CritRevNeurobiol.v13.i1
37
Salata B Kluczna A Dzierżanowski T . Opioid-Induced sexual dysfunction in cancer patients. Cancers (Basel). (2022) 14(16):4046. doi: 10.3390/cancers14164046
38
Lee KH Abas F Mohamed Alitheen NB Shaari K Lajis NH Israf DA et al . Chemopreventive effects of a curcumin-like diarylpentanoid [2,6-bis(2,5-dimethoxybenzylidene)cyclohexanone] in cellular targets of rheumatoid arthritis in vitro. Int J Rheumati Dis. (2015) 18:616–27. doi: 10.1111/apl.2015.18.issue-6
39
Fan HW Liu GY Zhao CF Li XF Yang XY . Differential expression of COX-2 in osteoarthritis and rheumatoid arthritis. Genet Mol research: GMR. (2015) 14:12872–9. doi: 10.4238/2015.October.21.7
40
De Cata A D'Agruma L Tarquini R Mazzoccoli G . Rheumatoid arthritis and the biological clock. Expert Rev Clin Immunol. (2014) 10:687–95. doi: 10.1586/1744666X.2014.899904
41
Spencer-Green G Spencer-Green E . Nonsteroidal therapy of rheumatoid arthritis and osteoarthritis: how physicians manage treatment failures. J Rheumatol. (1998) 25:2088–93.
42
O'Donnell AB Araujo AB Goldstein I McKinlay JB . The validity of a single-question self-report of erectile dysfunction. Results from the Massachusetts Male Aging Study. J Gen Internal Med. (2005) 20:515–9. doi: 10.1111/j.1525-1497.2005.0076.x
43
Peeters GM Alshurafa M Schaap L de Vet HC . Diagnostic accuracy of self-reported arthritis in the general adult population is acceptable. J Clin Epidemiol. (2015) 68:452–9. doi: 10.1016/j.jclinepi.2014.09.019
Summary
Keywords
arthritis, erectile dysfunction, NHANES, osteoarthritis, sexual dysfunction
Citation
Liu C, Lei Q, Li J and Liu W (2024) Arthritis increases the risk of erectile dysfunction: Results from the NHANES 2001-2004. Front. Endocrinol. 15:1390691. doi: 10.3389/fendo.2024.1390691
Received
23 February 2024
Accepted
19 June 2024
Published
03 July 2024
Volume
15 - 2024
Edited by
Mario Salazar-Paramo, University of Guadalajara, Mexico
Reviewed by
Binghao Bao, China-Japan Friendship Hospital, China
Peng-Yu Zhong, Nanchong Central Hospital, China
Updates
Copyright
© 2024 Liu, Lei, Li and Liu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Weihui Liu, weihuiliu1001@126.com; Jianwei Li, jianweili2024@163.com
†These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.